(Q51820698)

13 April 2018

title

SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. (English)

1 reference

13 April 2018

1 reference

5

Moussa Youdim

1 reference

13 April 2018

Ehud Susser

2

object named as

Ehud Susser

1 reference

13 April 2018

Lena Danovich

3

object named as

Lena Danovich

1 reference

13 April 2018

Orly Weinreb

7

object named as

Orly Weinreb

1 reference

13 April 2018

author name string

Henry Silver

1

1 reference

13 April 2018

Warren Bilker

4

1 reference

13 April 2018

Vladimir Goldin

6

1 reference

13 April 2018

publication date

16 December 2010

1 reference

13 April 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

13 April 2018

volume

14

1 reference

13 April 2018

issue

5

1 reference

13 April 2018

page(s)

573-584

1 reference

13 April 2018

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Protein kinase C overactivity impairs prefrontal cortical regulation of working memory.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Effects of Fluvoxamine Treatment on the in Vivo Binding of [F-18]FESP in Drug Naive Depressed Patients: A Pet Study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Altered platelet serotonin 5-HT2A receptor density but not second messenger inositol trisphosphate levels in drug-free schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Stress signalling pathways that impair prefrontal cortex structure and function

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

BDNF in schizophrenia, depression and corresponding animal models

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Cortical inhibitory neurons and schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Human peripheral blood mononuclear cells express GABAA receptor subunits.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Low Brain-Derived Neurotrophic Factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Human platelets contain brain-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Fluoxetine partly exerts its actions through GABA: a neurochemical evidence

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Lymphocytes as a neural probe: potential for studying psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Overexpression of serotonin receptor and transporter mRNA in blood leukocytes of antipsychotic-free and antipsychotic-naïve schizophrenic patients: gender differences

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Protein kinase C regulation of GABAA receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

The onset and time course of response of negative symptoms to add-on fluvoxamine treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Working memory deficit as a core neuropsychological dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Neurotransmitters drive combinatorial multistate postsynaptic density networks.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Add-on Fluvoxamine Improves Primary Negative Symptoms: Evidence for Specificity From Response Analysis of Individual Symptoms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Subunit-specific association of protein kinase C and the receptor for activated C kinase with GABA type A receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001471

7 January 2021

10.1017/S1461145710001471

Identifiers

DOI

1 reference

13 April 2018

1 reference

13 April 2018